Is Wegovy Good for Weight Loss? Here Is What the Clinical Evidence Actually Shows

You have read the headlines. Here is what the trial data behind them actually says.

If you have arrived here after seeing the "15% weight loss" figure quoted in the news, you are right to want more context before deciding anything. That number comes from the STEP 1 trial, published in the New England Journal of Medicine: 1,961 adults with obesity or overweight and at least one weight-related condition, randomised to semaglutide 2.4 mg weekly or placebo over 68 weeks, all alongside structured lifestyle support. The semaglutide group lost an average of 14.9% of their starting body weight. The placebo group lost 2.4%. That is not a marginal difference.

Context matters, though. An average is exactly that. Some participants lost considerably more; others less. People with type 2 diabetes tend to lose a smaller proportion, which is why Wegovy's licensed population distinguishes between those with and without diabetes. The trial also ran alongside dietary and activity support, Wegovy is licensed as an adjunct to a reduced-calorie diet and increased physical activity, not as a standalone fix. That framing is deliberate and clinically meaningful.

The STEP 1 result was already striking for a licensed medicine. Then, in January 2026, the MHRA approved a higher 7.2 mg maintenance dose. Trials at that dose reported average weight loss of around 20.7% over 72 weeks, bringing semaglutide much closer to tirzepatide's headline figures. For context on how the two compare, our overview of semaglutide as a weight-loss medicine goes into detail on the full evidence picture.

What makes semaglutide work, and why that matters for realistic expectations

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone the gut releases after eating; it signals to the brain that food has arrived, slows gastric emptying, and reduces the drive to keep eating. In people living with obesity, that signalling is often blunted. Semaglutide provides a sustained, pharmacological version of the same signal, once a week from a pre-filled injector pen.

The reason this matters for your expectations is that the drug addresses a biological mechanism, not a behavioural one. Many people find that the constant mental noise around food (the urge to finish a plate, the pull toward a snack two hours after dinner) genuinely quietens on treatment. That is the GLP-1 pathway doing what it is supposed to do. You can read more about how semaglutide interacts with gut hormones if you want the underlying science.

The practical implication: most people do not feel they are white-knuckling a diet. The medicine changes the appetite signal; the lifestyle changes become easier to sustain. But the lifestyle element still matters. Trials showed better outcomes when diet and activity support ran alongside the medicine, and this is baked into the UK licence. The NHS medicine information page for semaglutide covers this framing clearly.

For men specifically, body-composition patterns and starting weight can affect how the results look, there is a dedicated look at Wegovy and weight loss in men if that is relevant to your situation.

The side effects most people ask about, and the ones that catch people off guard

The most common side effects are gastrointestinal: nausea, constipation, diarrhoea, indigestion, and sometimes vomiting or burping. They tend to peak in the days after a new dose or a dose increase, then settle. For most people, starting at the lowest dose (0.25 mg) and titrating slowly is what keeps this manageable. Fatigue and headache are also reported, particularly early on.

A smaller number of people experience more significant problems. Pancreatitis (inflammation of the pancreas) is a known but infrequent risk. Seek urgent medical help for severe abdominal pain that spreads to your back, especially if accompanied by vomiting and not settling. Gallbladder problems and, in people with diabetes, changes in diabetic eye disease have also been reported. These are not reasons to avoid the medicine if you are clinically suitable, but they are reasons why prescriber oversight throughout treatment is not optional.

Any suspected side effect can and should be reported at the MHRA's Yellow Card scheme. That data is how regulators track signals in real-world use, it is genuinely useful, not just a formality. If you are deciding whether Wegovy is a good fit given a particular health situation, the full Wegovy treatment overview covers contraindications and who should discuss their history carefully with a prescriber.

Two things worth saying plainly: Wegovy is not recommended in pregnancy, breastfeeding, or for anyone trying to conceive. It is not licensed for people under 18. These are absolute boundaries, not areas for clinical judgement.

So is Wegovy a good option, and how do you find out if it is right for you?

For most people who meet the licence criteria and do not have a contraindication, the clinical evidence supports it as a genuinely effective medicine. If you want a thorough look at whether Wegovy is good as a treatment, weighing the trial results against real-world considerations, we cover that in detail separately. Whether it is the right medicine for you specifically is a different question, and one that belongs with a prescriber who can look at your full picture.

If you are comparing Wegovy with Ozempic (which is also semaglutide but licensed for type 2 diabetes, not weight management) the distinction matters. Our page on how Wegovy compares to Ozempic for weight loss explains why the two are not interchangeable for this purpose. If you are weighing Wegovy against other licensed options, the treatment options overview lays out what is available.

One thing people rarely mention but feel acutely: there is often a mix of hope and scepticism when you reach this point of researching a medicine like this. That is entirely reasonable. The evidence is genuinely strong. But it also needs to be applied to your actual circumstances by someone who knows them. That is what an honest clinical consultation is for. Check your eligibility and speak to our prescribers through the free consultation, a real clinician reviews your answers the same day.